Optimizatsiya taktiki vedeniya patsientok s vospalitel'nymi zabolevaniyami organov malogo taza

Full Text

Abstract

About the authors

A V Shurshalina

References

  1. Гинекология: национальное руководство. Под ред. В.И.Кулакова, И.Б.Манухина, Г.М.Савельевой. М.: ГЭОТАР-Медиа, 2011; с. 704-24.
  2. Blake DR. Identification of symptoms that indicate a pelvic examination is necessary to exclude PID in adolescent women. J Pediatr Adolesc Gynecol 2003; 16 (1): 25-30.
  3. Boeke AJ. The risk of pelvic inflammatory disease with urogenital infection with Chlamydia trachomatis. Ned Tijdschr Geneeskd 2005; 149 (16): 878-84.
  4. Boothby M, Page J, Pryor R, Ross JD. A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease. Int J STD AIDS 2010; 21 (3): 195-7.
  5. Bebear CM, Barbeyrac B, Pereyre S. Activity of moxifloxacin against theurogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis. Clin Microbiol Infect 2008; 14: 801-5.
  6. CDC. Sexually Transmitted Disease Treatment Guidelines. Pelvic Inflammatory Disease. MMWR 2010; 59: 12.
  7. Cohen CR, Manhart LE, Bukusi EA et al. Association between Mycoplasma genitalium and acute endometritis. Lancet 2002; 359: 765-6.
  8. European guideline (IUSTI/WHO) for the management of STI 2010. http://www.iusti.org
  9. Heystek M, Ross JD; PID Study Group. A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009; 20 (10): 690-5.
  10. Heystek M, Tellarini M, Schmitz H et al. Efficacy and safety of moxifloxacin vs ciprofloxacin plus doxycycline plus metronidazole for the treatment of uncomplicated pelvic inflammatory disease (PID). J Antimicrob Chemother 1999; 44 (Suppl. A): 143.
  11. Hillis SD, Joesoef , Marchbanks PA et al. Delayed care of pelvic inflammatory disease as a risk factor for impaired fertility. Am J Obstet Gynecol 1993; 163: 1503-9.
  12. Jaiyeoba O, Soper DE. A practical approach to the diagnosis of pelvic inflammatory disease. Infect Dis Obstet Gynecol 2011; 2011: 753037.
  13. Jernberg E, Moghaddam A, Moi H. Azithromycin and moxifloxacin for microbiological cure of Mycoplasma genitalium infection: an open study. Int J STD AIDS 2008; 19 (10): 676-9.
  14. Judlin P, Liao Q, Liu Z et al. Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG 2010; 117 (12): 1475-84.
  15. Lin HW, Tu YY, Lin SY. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. Lancet Oncol 2011; 12 (9): 900-4.
  16. Pascual A, García I, Ballesta S. Uptake and intracellular activity of moxifloxacin in human neutrophiles and tissue-cultured epithelial cells. Antimicrob. Agents Chemother 1999; 43 (1): 12-5.
  17. RCOG Green Top Guidelines - Management of Pelvic Inflammatory Disease (2003, 2009). www.rcog.org.uk
  18. Ross JD, Cronjé HS, Paszkowski T, Rakoczi I. MAIDEN Study Group. Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multi-centers, double blind, randomized trial. Sex Transm Infect 2006; 82 (6): 446-51.
  19. Solomkin J, Zhao YP, Ma EL. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with community-origin complicated intra-abdominal infections. Int J Antimicrob Agents 2009; 34 (5): 439-45.
  20. Stass H, Kubitza D, Aydeniz B et al. Penetration and accumulation of moxifloxacin in uterine tissue. Int J Gynaecol Obstet 2008; 102 (2): 132-6.
  21. Stein GE, Schooley S, Tyrrell KL. Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens. Anaerobe 2008; 14 (1): 8-12.
  22. Sweet RL. Pelvic Inflammatory Disease: Current Concepts of Diagnosis and Management. Curr Infect Dis Rep 2012; 2.

Statistics

Views

Abstract: 49

Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies